Advanced solid tumours, Phase 1/2
KY1044 is a human monoclonal IgG1 that selectively binds to Inducible T cell CO-stimulator (ICOS), a protein expressed at high levels on immunosuppressive regulatory T cells and at lower levels on effector T cells. KY1044 is designed to exert anti-tumour activity through preferential depletion of intra-tumoral regulatory T cells and stimulation (agonism) of ICOS-positive effector T cells.
KY1044 can also improve the ratio of intra-tumoral effector T cells to regulatory T cells which promotes an anti-tumour immune response. In preclinical studies, we have demonstrated that KY1044 can promote a significant and long-lasting anti-tumour effect as monotherapy or as a synergistic combination with anti-PD-L1. We are currently conducting a Phase 1/2 clinical trial of KY1044 in patients with advanced solid tumours as a monotherapy and in combination with atezolizumab. We expect safety and activity data from the monotherapy trial in the first half of 2020 and initial safety and activity data from the combination in the second half of 2020.